Terms: = Liver cancer AND HER1, YOR227W AND Prognosis
4 results:
1. Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report.
Yue L; Wentao L; Xin Z; Jingjing H; Xiaoyan Z; Na F; Tonghui M; Dalin L
Medicine (Baltimore); 2020 Dec; 99(51):e23406. PubMed ID: 33371069
[TBL] [Abstract] [Full Text] [Related]
2. Role of ErbB/HER family of receptor tyrosine kinases in cholangiocyte biology.
Pellat A; Vaquero J; Fouassier L
Hepatology; 2018 Feb; 67(2):762-773. PubMed ID: 28671339
[TBL] [Abstract] [Full Text] [Related]
3. Factors predicting lapatinib efficacy in HER-2+ metastatic breast carcinoma: Does it work better in different histologic subtypes?
Göksu SS; Bozcuk H; Koral L; Çakar B; Gündüz S; Tatlı AM; Arslan D; Uysal M; Koçer M; Artaç M; Karabulut B; Coşkun HS; Özdoğan M; Savaş B
Indian J Cancer; 2015; 52(4):517-9. PubMed ID: 26960462
[TBL] [Abstract] [Full Text] [Related]
4. Activated cMET and IGF1R-driven PI3K signaling predicts poor survival in colorectal cancers independent of KRAS mutational status.
Lee J; Jain A; Kim P; Lee T; Kuller A; Princen F; In-GuDo ; Kim SH; Park JO; Park YS; Singh S; Kim HC
PLoS One; 2014; 9(8):e103551. PubMed ID: 25090459
[TBL] [Abstract] [Full Text] [Related]
